http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017509622-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2015-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017509622-A |
| titleOfInvention | Use of factor Xa inhibitors to treat and prevent bleeding events and related disorders in patients sensitive to vitamin K antagonists used as anticoagulants |
| abstract | The present invention is a method of treating or preventing bleeding events or hyperanticoagulation in a subject in need thereof, identified as being sensitive to a vitamin K antagonist such as warfarin, directly or indirectly. Methods are provided by administering to a subject a therapeutically effective amount of an FXa inhibitor, which may be an FXa inhibitor or warfarin or a VKA replacement drug or compound. The direct FXa inhibitor can be a small molecule edoxaban p-toluenesulfonate monohydrate, edoxaban, or a pharmaceutically acceptable salt and / or hydrate thereof. In embodiments, the subject is one or more genetic polymorphisms in the genes CYP2C9 and / or VKORC1, wherein the genetic polymorphism results in loss of function, reduced function or abnormal function of these genes and / or their protein products As well as being sensitive to warfarin. The present invention provides a safe and effective method for embolism, thrombosis, thromboembolism, etc. in a subject identified as having one or more genetic polymorphisms that require anticoagulant therapy and confers warfarin sensitivity. Methods are provided for administering FXa inhibitors or warfarin substitutes to reduce, prevent, reduce the risk, prevent the recurrence, or prevent the risk of the recurrence. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020520510-A |
| priorityDate | 2014-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 398.